What is the appropriate dosing regimen for bupropion (sustained-release) in a Parkinson’s disease patient receiving rasagiline who requires a non‑serotonergic antidepressant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bupropion Dosing in Parkinson's Disease Patients on Rasagiline

For a Parkinson's disease patient receiving rasagiline who requires bupropion as a non-serotonergic antidepressant, start with bupropion sustained-release 150 mg once daily in the morning for 3 days, then increase to 150 mg twice daily (maximum 300 mg/day), with the second dose given before 3 p.m. to minimize insomnia risk. 1

Dosing Algorithm

Initial Titration

  • Days 1-3: 150 mg once daily in the morning
  • Day 4 onwards: 150 mg twice daily (total 300 mg/day) if tolerated
  • Maximum dose: 300 mg/day (do not exceed) 1

Timing Considerations

  • Give the second dose before 3 p.m. to minimize insomnia 2
  • This activating medication can cause rapid improvement in energy levels 2

Duration of Trial

  • Allow 4-6 weeks for adequate therapeutic assessment 1
  • Continue for at least 7-12 weeks if showing benefit 1

Critical Safety Considerations for This Specific Patient

Seizure Risk

Bupropion is contraindicated in patients with seizure disorders or factors that lower seizure threshold 1. In Parkinson's disease patients, this is particularly relevant because:

  • Bupropion lowers seizure threshold
  • The combination with rasagiline does not create additional seizure risk beyond bupropion alone
  • One older study showed bupropion had mild efficacy in PD but side effects were dose-limiting in 25% of patients 3

Drug Interaction with Rasagiline

There is NO contraindication to combining bupropion with rasagiline 4. The rasagiline FDA label specifically contraindicates MAO inhibitors and certain serotonergic agents (meperidine, tramadol, methadone, SSRIs), but bupropion is not listed as contraindicated 4. Bupropion is a dopamine/norepinephrine reuptake inhibitor, not a serotonergic agent, making it appropriate for use with rasagiline 5, 6, 5.

Rasagiline Dosing Context

Your patient is likely on rasagiline 0.5-1 mg once daily 4. This does not require bupropion dose adjustment, as there are no significant pharmacokinetic interactions between these medications.

Why Bupropion is Appropriate Here

Bupropion is an excellent choice for depression in Parkinson's disease patients on rasagiline because:

  • It avoids serotonergic mechanisms that could interact with MAO-B inhibitors
  • It has activating properties that may help with PD-related apathy 2
  • Historical data shows mild anti-parkinsonian effects 3
  • It does not worsen motor symptoms

Common Pitfalls to Avoid

  1. Do not use with agitated patients - bupropion is activating and should be avoided in agitated depression 2

  2. Do not confuse with MAO-A inhibitors - rasagiline is a selective MAO-B inhibitor; the contraindication for non-selective MAOIs does not apply to bupropion

  3. Do not exceed 300 mg/day - higher doses significantly increase seizure risk 1

  4. Monitor for neuropsychiatric effects - though uncommon, monitor for worsening depression or suicidal ideation, particularly in the first weeks 1

  5. Avoid late-day dosing - the second dose must be given before 3 p.m. to prevent insomnia 2

Alternative Dosing in Special Circumstances

If the patient is taking CYP2D6 inhibitors or has hepatic/renal impairment, standard bupropion dosing still applies, as these factors primarily affect other antidepressants. However, if seizure risk factors emerge, consider maintaining the lower 150 mg once-daily dose rather than escalating.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.